Alliance Global Partners Boosts Tonix Pharmaceuticals (NASDAQ:TNXP) Price Target to $11.00

Tonix Pharmaceuticals (NASDAQ:TNXP) had its price target hoisted by Alliance Global Partners from $6.00 to $11.00 in a research report report published on Monday morning, Benzinga reports. Alliance Global Partners currently has a buy rating on the stock.

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Friday, June 14th. They set a sell rating for the company.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP opened at $0.53 on Monday. The business has a fifty day moving average price of $2.36 and a two-hundred day moving average price of $6.55. The stock has a market capitalization of $9.20 million, a PE ratio of 0.00 and a beta of 2.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.47 and a quick ratio of 0.87. Tonix Pharmaceuticals has a fifty-two week low of $0.52 and a fifty-two week high of $58.24.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Monday, May 13th. The company reported ($5.76) EPS for the quarter, beating the consensus estimate of ($16.64) by $10.88. The firm had revenue of $2.48 million during the quarter, compared to the consensus estimate of $4.00 million. As a group, equities analysts predict that Tonix Pharmaceuticals will post -34.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC raised its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,770,000 shares of the company’s stock after acquiring an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned approximately 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.